MA56027A - Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40 - Google Patents
Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40Info
- Publication number
- MA56027A MA56027A MA056027A MA56027A MA56027A MA 56027 A MA56027 A MA 56027A MA 056027 A MA056027 A MA 056027A MA 56027 A MA56027 A MA 56027A MA 56027 A MA56027 A MA 56027A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- providing safe
- safe administration
- administration
- providing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853488P | 2019-05-28 | 2019-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56027A true MA56027A (fr) | 2022-04-06 |
Family
ID=70918772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056027A MA56027A (fr) | 2019-05-28 | 2020-05-27 | Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230174658A1 (https=) |
| EP (1) | EP3976651A1 (https=) |
| JP (2) | JP7755999B2 (https=) |
| KR (1) | KR20220012918A (https=) |
| CN (1) | CN113939535A (https=) |
| AU (1) | AU2020284706A1 (https=) |
| BR (1) | BR112021023906A2 (https=) |
| CA (1) | CA3142226A1 (https=) |
| IL (1) | IL288288A (https=) |
| MA (1) | MA56027A (https=) |
| MX (1) | MX2021014572A (https=) |
| SG (1) | SG11202112909SA (https=) |
| WO (1) | WO2020240434A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122355A2 (en) * | 2021-12-24 | 2023-06-29 | Sapience Therapeutics, Inc. | Methods of treating or preventing infusion-related reactions |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070003557A1 (en) * | 2005-04-21 | 2007-01-04 | Andres Forero | Method for treating cancer using premedication |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| CA2957146A1 (en) * | 2014-08-12 | 2016-02-18 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| WO2018160917A1 (en) | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
-
2020
- 2020-05-27 AU AU2020284706A patent/AU2020284706A1/en active Pending
- 2020-05-27 EP EP20729226.9A patent/EP3976651A1/en active Pending
- 2020-05-27 CA CA3142226A patent/CA3142226A1/en active Pending
- 2020-05-27 CN CN202080039748.6A patent/CN113939535A/zh active Pending
- 2020-05-27 US US17/613,632 patent/US20230174658A1/en not_active Abandoned
- 2020-05-27 MA MA056027A patent/MA56027A/fr unknown
- 2020-05-27 KR KR1020217042271A patent/KR20220012918A/ko not_active Ceased
- 2020-05-27 BR BR112021023906A patent/BR112021023906A2/pt unknown
- 2020-05-27 SG SG11202112909SA patent/SG11202112909SA/en unknown
- 2020-05-27 MX MX2021014572A patent/MX2021014572A/es unknown
- 2020-05-27 WO PCT/IB2020/055023 patent/WO2020240434A1/en not_active Ceased
- 2020-05-27 JP JP2021570263A patent/JP7755999B2/ja active Active
-
2021
- 2021-11-22 IL IL288288A patent/IL288288A/en unknown
-
2025
- 2025-10-06 JP JP2025168433A patent/JP2026004525A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020240434A1 (en) | 2020-12-03 |
| CN113939535A (zh) | 2022-01-14 |
| JP2022534494A (ja) | 2022-08-01 |
| MX2021014572A (es) | 2022-03-17 |
| KR20220012918A (ko) | 2022-02-04 |
| IL288288A (en) | 2022-01-01 |
| BR112021023906A2 (pt) | 2022-01-25 |
| AU2020284706A1 (en) | 2021-12-16 |
| EP3976651A1 (en) | 2022-04-06 |
| JP2026004525A (ja) | 2026-01-14 |
| US20230174658A1 (en) | 2023-06-08 |
| JP7755999B2 (ja) | 2025-10-17 |
| SG11202112909SA (en) | 2021-12-30 |
| CA3142226A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53920A (fr) | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 | |
| EP4025214A4 (en) | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | |
| EP3315512A4 (en) | METHOD FOR SELECTIVELY PREPARING AN ANTIBODY-ACTIVE CONJUGATE | |
| EP3710009A4 (en) | PROCESS FOR THE DISSOLUTION OF BENZODIAZEPINE-2-ONE AND BENZOAZEPINE-2-ONE DERIVATIVES | |
| EP4056177A4 (en) | CANNABINOID NANOMICELLS PREPARATION AND METHOD OF MANUFACTURE THEREOF | |
| EP3819284A4 (en) | CATALYST FOR THE PRODUCTION OF 1,2-PENTANEDIOL AND PROCESS FOR THE PRODUCTION OF 1,2-PENTANEDIOL USING THE SAME | |
| EP3835411C0 (en) | RECOMBINANT YEAST, PROCESS FOR THEIR PRODUCTION AND ITS USE IN THE MANUFACTURE OF TYROSOL AND DERIVATIVES | |
| EP3927701A4 (en) | PROCESSES FOR THE PREPARATION OF ANTHRANILDIAMIDES AND INTERMEDIATE PRODUCTS THEREOF | |
| MA56102A (fr) | Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée | |
| EP3734268A4 (en) | SIMPLIFIED METHOD OF QUANTIFYING MONOCLONAL ANTIBODIES | |
| MA55967A (fr) | Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple | |
| EP3402771A4 (en) | METHOD FOR PRODUCING AN OLEF-CONTAINING FLUOR | |
| EP3876307A4 (en) | FOIL AND MANUFACTURING PROCESS | |
| EP3970744A4 (en) | STABLE SECUKINUMABINJECTION AND METHODS OF PRODUCTION | |
| EP3897717A4 (en) | Methods of producing heterodimeric antibodies | |
| EP3644062C0 (en) | METHOD FOR PREDICTING THE RESPONSE OF ESOPIAL CANCER TO ANTI-ERBB3 ANTIBODIES THERAPY | |
| EP3432925A4 (en) | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY | |
| MA56027A (fr) | Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40 | |
| EP3347099A4 (en) | CYCLOPHOSPHAMID ANALOGUES FOR USE AS IMMUNOGENS AND ASSAY CONJUGATES FOR AN IMMUNOASSAY OF CYCLOPHOSPHAMIDE AND IFOSFAMID | |
| EP3591399A4 (en) | METHOD FOR DETECTING A COMPONENT OF AN ANTIBODY-ACTIVE SUBSTANCE CONJUGATE | |
| IL288690A (en) | Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis | |
| EP3947448A4 (en) | PROCEDURE FOR ADMINISTRATION OF AN ANTI-IFN ALPHA/OMEGA ANTIBODY | |
| EP3902792A4 (en) | PROCESS FOR THE PREPARATION OF ANTHRANILAMIDES | |
| MA51870A (fr) | Procédé pour la préparation de composés coupleurs de médicaments | |
| EP3644335A4 (en) | METHOD FOR PRODUCING AN ANODE ACTIVE MATERIAL FOR PSEUDO CONDENSER |